1
|
Garay JP, Korkola JE, Gray JW. Abstract P3-03-04: Sensitivity to lapatinib differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA and relies on production of PIP3. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-03-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: HER2 is amplified in nearly 25% of all primary breast cancers. Lapatinib is a targeted therapy that inhibits overactive HER2 signaling but invariably resistance to this targeted therapy occurs in a substantial number of patients. The PI3K-AKT axis is the major pathway downstream of HER2 signaling. Activated PI3-kinase phosphorylates the membrane lipid PIP2 resulting in PIP3. PIP3 is as a docking site for pleckstrin homology (PH) domain proteins, such as the AKT. AKT influences a variety of pathways inside the cell involving cell growth, regulation of apoptosis, glucose metabolism, and others. Mutations in the gene PIK3CA deregulate this signaling axis. In HER2 amplified cancers, co-occurrence of PIK3CA mutations have been reported in approximately 20% of cases. Hotspot mutations of PIK3CA translate to changes in either the helical domain (E545K) or kinase domain (H1047R) of the protein and these two hotspots comprise over 80% of all reported oncogenic mutations across all tumor types. Crystallographic studies have shown conformational differences between the two hotspot mutations in PIK3CA, yet it is unclear if functional differences exist between the two mutations.
Methods: We generated isogenic knockin mutants of the helical domain (E545K) and kinase domain (H1047R) of PIK3CA in the HER2-amplified breast cancer cell line SK-BR-3. Mutant and parental cell lines were subjected to drug sensitivity assays measured by cell growth during prolonged exposure to drug. We investigated changes of relevant intracellular signaling pathways via western blot analysis. Additionally, we used immunofluorescence of PIP3 and confocal microscopy to visualize cellular differences in the production of this signaling molecule.
Results: Our results demonstrate a distinction between the helical domain (E545K) and kinase domain (H1047R) mutations of PIK3CA. Mutations in the helical domain do not confer resistance to lapatinib while mutations in the kinase domain do. This is a result of sustained AKT signaling even in the presence of high dose lapatinib in cells with the kinase domain mutation. We also show the PTEN loss phenocopies this phenomenon. Finally, we show that kinase domain mutations allow the protein to generate significantly higher levels of PIP3 which is the necessary molecule for downstream signaling through AKT but helical domain mutations do not.
Conclusion: This phenotypic disparity between helical and kinase domain mutations of PIK3CA has important clinical implications. It is possible to imagine that in a heterogeneous tumor in which some cells are wildtype and some cells carry this mutation for PIK3CA treatment with lapatinib will select for cells with the mutation conferring a growth advantage. Our results show that only H1047R mutant cells demonstrate lapatinib resistance and this is achieved via sustained AKT signaling through continual production of PIP3. Altogether, we demonstrate a mechanism of de novo resistance to HER2-targeted therapy in breast cancer.
Citation Format: Garay JP, Korkola JE, Gray JW. Sensitivity to lapatinib differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA and relies on production of PIP3 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-03-04.
Collapse
Affiliation(s)
- JP Garay
- Oregon Health & Science University, Portland, OR
| | - JE Korkola
- Oregon Health & Science University, Portland, OR
| | - JW Gray
- Oregon Health & Science University, Portland, OR
| |
Collapse
|
2
|
Korkola JE, Watson S, Smith R, Thompson W, Dame M, Liby T, Bucher E, Sudar D, Nederlof M, Heiser L, Gray JW. Abstract PD5-01: Microenvironment microarrays show that microenvironment mediated resistance mechanisms to lapatinib differ between basal and luminal HER2+ cells. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd5-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cell lines represent a valuable model system for the study of breast cancer, as they capture the cellular diversity, mutational spectrum, expression subtypes, and genomic alterations that are observed in clinical specimens. However, like any model system, cell lines are imperfect, particularly when it comes to capturing the effects of the myriad of signals and interactions they encounter in their microenvironment (ME). We are utilizing a technology known as microenvironment microarrays (MEMA) to begin to unravel the consequences of interactions of breast cancer cells with the ME. MEMA consist of thousands of unique combinations of insoluble matrix proteins that are printed to form growth pads with ligands added to the media. Cells are grown on the MEMA spots and the effects of the specific ME that they are exposed to can be read out using immunofluorescent stains of interest. When combined with automated imaging and sophisticated image processing and analysis, the MEMA platform enables the identification of specific ME conditions that alter the phenotypes of cells. We have applied MEMA to understand both baseline responses to the ME as well as how the ME might mediate response to therapeutics. We performed a pilot experiment to investigate the effects of the ME on the response to the HER2-targeted inhibitor lapatinib. We found that HCC1954 cells continued to proliferate robustly in the presence of HGF when treated with 500 nM lapatinib. In contrast, AU565 cells were proliferative in the presence of NRG1 and lapatinib, but not HGF. Focused follow up studies showed that HGF is effective in rescuing only basal HER2+ cells, while NRG1 is effective in rescuing only luminal subtype HER2+cells. Rescue with the relevant growth factor was also observed in 3-d matrigel studies, showing this was not an artifact of the 2-d culture system. We investigated the effects of drug combinations using lapatinib plus drugs that target either MET (Crizotinib) or HER3-HER2 dimers (pertuzumab). These drug combinations were able to overcome the resistance mediated by HGF and NRG1 in basal and luminal cells respectively. We found the effectiveness of pertuzumab particularly interesting, given that lapatinib should still be inhibiting HER2 kinase activity. Parallel studies found that inhibitors targeting other kinase receptors such as IGF1R partially restored sensitivity to HER2 in the presence of NRG1, suggesting a role for such receptors in the resistance. Immunoprecipitation studies showed that IGF1R co-immunoprecipitated with HER2/HER3 when pertuzumab was absent, but that additional of pertuzumab abrogated the binding of IGF1R to HER3, suggesting the formation of HER2-dependent higher order structures that can signal even when HER2 is inhibited. These studies highlight the importance of understanding the effects of the ME on cancer cells, and demonstrate the differences between ME factors that can confer resistance to HER2 targeted inhibitors in basal and luminal HER2+ cells. These findings suggest that both subtype and ME composition may be important in determining response to combinatorial treatments and may be useful to inform clinical decision making.
Citation Format: Korkola JE, Watson S, Smith R, Thompson W, Dame M, Liby T, Bucher E, Sudar D, Nederlof M, Heiser L, Gray JW. Microenvironment microarrays show that microenvironment mediated resistance mechanisms to lapatinib differ between basal and luminal HER2+ cells [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD5-01.
Collapse
Affiliation(s)
- JE Korkola
- Oregon Health & Science University, Portland, OR
| | - S Watson
- Oregon Health & Science University, Portland, OR
| | - R Smith
- Oregon Health & Science University, Portland, OR
| | - W Thompson
- Oregon Health & Science University, Portland, OR
| | - M Dame
- Oregon Health & Science University, Portland, OR
| | - T Liby
- Oregon Health & Science University, Portland, OR
| | - E Bucher
- Oregon Health & Science University, Portland, OR
| | - D Sudar
- Oregon Health & Science University, Portland, OR
| | - M Nederlof
- Oregon Health & Science University, Portland, OR
| | - L Heiser
- Oregon Health & Science University, Portland, OR
| | - JW Gray
- Oregon Health & Science University, Portland, OR
| |
Collapse
|
3
|
Gray JW. Response to: 'Interpreting the guidelines for cleaning up after carbapenemase-producing organisms: the devil's in the dilution'. J Hosp Infect 2016; 94:109-10. [PMID: 27365131 DOI: 10.1016/j.jhin.2016.06.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 06/09/2016] [Indexed: 11/29/2022]
Affiliation(s)
- J W Gray
- Microbiology, Birmingham Children's Hospital, Birmingham, UK.
| |
Collapse
|
4
|
Gray JW. HIS Middle East Infection Prevention Summit 2015. J Hosp Infect 2015; 91:187. [PMID: 26337781 PMCID: PMC7134400 DOI: 10.1016/j.jhin.2015.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 08/12/2015] [Indexed: 11/05/2022]
Affiliation(s)
- J W Gray
- Editor, Journal of Hospital Infection, 162 King's Cross Road, London WC1X 9DH, UK.
| |
Collapse
|
5
|
Muir A, Suviste J, Gray JW. Preliminary experience of environmental monitoring using sponge swabs on a neonatal intensive care unit. J Hosp Infect 2013; 83:266-7. [PMID: 23332562 DOI: 10.1016/j.jhin.2012.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2012] [Accepted: 11/30/2012] [Indexed: 11/17/2022]
|
6
|
Gray JW, Suviste J. Three years' experience of screening for meticillin-resistant Staphylococcus aureus in obstetrics. J Hosp Infect 2012; 83:61-3. [PMID: 23102817 DOI: 10.1016/j.jhin.2012.09.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 09/06/2012] [Indexed: 10/27/2022]
Abstract
There are few data on meticillin-resistant Staphylococcus aureus (MRSA) screening in obstetrics, a largely healthy population that should be at lower risk for MRSA than most hospitalized populations. From January 2009 to December 2011 nose swabs were screened from 5548 of 21,770 (25.5%) women who delivered at Birmingham Women's Hospital. Only 29 (0.5%) were MRSA positive: MRSA infections occurred later in three cases. MRSA infections occurred in a further 13 mother-infant pairs, including six cases where mothers were MRSA screen negative. Seventeen mothers had risk factors for MRSA. MRSA is not widespread in obstetrics, and large-scale screening of nasal swabs is of limited value in preventing MRSA-related morbidity in this population.
Collapse
Affiliation(s)
- J W Gray
- Department of Microbiology, Birmingham Women's Hospital, Edgbaston, Birmingham, UK.
| | | |
Collapse
|
7
|
Gray JW, Milner PJ, Edwards EH, Daniels JP, Khan KS. Feasibility of using microbiology diagnostic tests of moderate or high complexity at the point - of - care in a delivery suite. J OBSTET GYNAECOL 2012; 32:458-60. [PMID: 22663318 DOI: 10.3109/01443615.2012.673034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Point-of-care testing (POCT) is one of the fastest growing sectors of laboratory diagnostics. Most tests in routine use are haematology or biochemistry tests that are of low complexity. Microbiology POCT has been constrained by a lack of tests that are both accurate and of low complexity. We describe our experience of the practical issues around using more complex POCT for detection of Group B streptococci (GBS) in swabs from labouring women. We evaluated two tests for their feasibility in POCT: an optical immune assay (Biostar OIA Strep B, Inverness Medical, Princetown, NJ) and a PCR (IDI-Strep B, Cepheid, Sunnyvale, CA), which have been categorised as being of moderate and high complexity, respectively. A total of 12 unqualified midwifery assistants (MA) were trained to undertake testing on the delivery suite. A systematic approach to the introduction and management of POC testing was used. Modelling showed that the probability of test results being available within a clinically useful timescale was high. However, in the clinical setting, we found it impossible to maintain reliable availability of trained testers. Implementation of more complex POC testing is technically feasible, but it is expensive, and may be difficult to achieve in a busy delivery suite.
Collapse
Affiliation(s)
- J W Gray
- Department of Microbiology, Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, UK.
| | | | | | | | | |
Collapse
|
8
|
Boudreau A, Yau C, Petrillo L, Stemke-Hale K, Mills GB, Gray JW, Wolf DM, van ‘t Veer LJ. P5-01-05: Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Mutations in the catalytic domain of phosphatidylinositol 3-kinase (PIK3CA) are among the most frequently observed activating mutations in breast cancer. We used the I SPY 1 TRIAL, a group of biologically and clinically high risk patients molecularly profiled and treated with neoadjuvant chemotherapy, to determine the frequency of mutations and their relationship to pathologic complete response (pCR) and outcomes, within the entire cohort and within subtypes defined by growth and hormone receptor (HR) expression.
Methods: Patients enrolled in the I-SPY 1 TRIAL had a tumor size ≥3.0cm and were administered a doxorubicin-containing regimen, followed by a taxane, prior to surgery. Sequenom single nucleotide polymorphism (SNP) profiling was performed on breast tumor genomic DNA isolated from a subset of patients (n=152). A total of 149 SNPs covering 16 genes (including PIK3CA and AKT1/2/3) were analyzed. Mutations were tested for association with estrogen receptor (ER), progesterone receptor (PgR), and HER2 status, as well as pCR, using Fisher's exact test; associations between mutations and recurrence-free survival (RFS) were measured by log-rank tests. pCR was defined as no invasive tumor present in either the breast or axillary lymph nodes following neoadjuvant treatment.
Results: Of 149 mutations profiled in the cohort, 13 of the SNPs were observed. PIK3CA mutations were the most frequently observed in the panel (15.1%), followed by AKT1(E17K; 2.7%), CTNNB1 (D32; 1.4%), NRAS(Q61; 0.7%), and FGFR2(N549; 0.7%). Mutations in PIK3CA or AKT1 was associated with ER-positivity (p=0.0047) and PgR-positivity (p=0.044). Within receptor subtypes, the frequencies of PIK3CA/AKT1 mutations were also significantly different (HR+HER2−: 27%:(18/68); HER2+ 20% (8/40) [HR+HER2+: 26%, HR-HER2+: 14%]; HR-HER2−: 0% (0/36), p<0.0008). Unlike previous reports (Loi et al, PNAS 2010), no significant association between PIK3CA/AKT mutation status and RFS was observed when we restricted our analysis to the adjuvant endocrine treated subset of the HR+HER2− patients (n=49; log rank p = 0.369). In contrast, and similar to cell line reports (Junttila et al, Cancer Cell 2009), PIK3CA mutations appears to associate with worse RFS within the small subset of trastuzumab treated HER2+ patients (n=22, 13 HR-HER2+, 9 HR+HER2−; log rank p=0.001), suggesting mutations may influence response. Similar analyses of a larger cohort are planned to confirm these observations.
Conclusions: Within the I-SPY 1 TRIAL cohort, PIK3CA and AKT1 mutations are much more frequent in the HR+ and HER2 subsets but are not predictive of response to therapy or outcome except potentially within the HER2+ subset. The potential link observed between activating PIK3CA/AKT mutations and trastuzumab resistance merits further investigation, as it may provide a clinical rationale for testing PIK3CA mutation status in HER2+ patients and investigating combinational therapies targeting this pathway, particularly in the HER2+HR+ subset which have an elevated risk for recurrence despite pCR and trastuzumab therapy.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-01-05.
Collapse
Affiliation(s)
- A Boudreau
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - C Yau
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - L Petrillo
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - K Stemke-Hale
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - GB Mills
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - JW Gray
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - DM Wolf
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| | - LJ van ‘t Veer
- 1The I-SPY 1 TRIAL Investigators, Esserman LJ. University of California, San Francisco; University of Texas MD Anderson Cancer Center; Oregon Health & Science University
| |
Collapse
|
9
|
Ong DCT, Ho YM, Rudduck C, Chin K, Kuo WL, Lie DKH, Chua CLM, Tan PH, Eu KW, Seow-Choen F, Wong CY, Hong GS, Gray JW, Lee ASG. LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer. Oncogene 2009; 28:4189-200. [PMID: 19734946 PMCID: PMC2844776 DOI: 10.1038/onc.2009.266] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Deletion of 11q23-q24 is frequent in a diverse variety of malignancies, including breast and colorectal carcinoma, implicating the presence of a tumor suppressor gene at that chromosomal region. We examined a 6-Mb region on 11q23 by high-resolution deletion mapping, using both loss of heterozygosity analysis and customized microarray comparative genomic hybridization. LARG (leukemia-associated Rho guanine-nucleotide exchange factor) (also called ARHGEF12), identified from the analysed region, is frequently underexpressed in breast and colorectal carcinomas with a reduced expression observed in all breast cancer cell lines (n=11), in 12 of 38 (32%) primary breast cancers, 5 of 10 (50%) colorectal cell lines and in 20 of 37 (54%) primary colorectal cancers. Underexpression of the LARG transcript was significantly associated with genomic loss (P=0.00334). Hypermethylation of the LARG promoter was not detected in either breast or colorectal cancer, and treatment of four breast and four colorectal cancer cell lines with 5-aza-2'-deoxycytidine and/or trichostatin A did not result in a reactivation of LARG. Enforced expression of LARG in breast and colorectal cancer cells by stable transfection resulted in reduced cell proliferation and colony formation, as well as in a markedly slower cell migration rate in colorectal cancer cells, providing functional evidence for LARG as a candidate tumor suppressor gene.
Collapse
Affiliation(s)
- DCT Ong
- Division of Medical Sciences, National Cancer Centre, Singapore
| | - YM Ho
- Division of Medical Sciences, National Cancer Centre, Singapore
| | - C Rudduck
- Department of Pathology, Singapore General Hospital, Singapore
| | - K Chin
- UCSF Comprehensive Cancer Center, University of California, San Francisco, CA, USA
| | - W-L Kuo
- UCSF Comprehensive Cancer Center, University of California, San Francisco, CA, USA
- Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - DKH Lie
- Division of Medical Sciences, National Cancer Centre, Singapore
| | - CLM Chua
- Division of Medical Sciences, National Cancer Centre, Singapore
| | - PH Tan
- Department of Pathology, Singapore General Hospital, Singapore
| | - KW Eu
- Department of Colorectal Surgery, Singapore General Hospital, Singapore
| | - F Seow-Choen
- Department of Colorectal Surgery, Singapore General Hospital, Singapore
| | - CY Wong
- Department of General Surgery, Singapore General Hospital, Singapore
| | - GS Hong
- Department of General Surgery, Singapore General Hospital, Singapore
| | - JW Gray
- UCSF Comprehensive Cancer Center, University of California, San Francisco, CA, USA
- Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - ASG Lee
- Division of Medical Sciences, National Cancer Centre, Singapore
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| |
Collapse
|
10
|
Schmid E, Zitzelsberger H, Braselmann H, Gray JW, Bauchinger M. Radiation-induced Chromosome Aberrations Analysed by Fluorescencein SituHybridization with a Triple Combination of Composite Whole Chromosome-specific DNA Probes. Int J Radiat Biol 2009; 62:673-8. [PMID: 1362760 DOI: 10.1080/09553009214552621] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Fluorescence in situ hybridization (FISH) with a combination of three composite whole chromosome-specific DNA probes for human chromosomes 1, 4 and 12 was used to analyse in vitro radiation-induced dicentrics and symmetrical translocations in peripheral lymphocytes. Translocations could be rapidly and efficiently detected by FISH. Their frequencies were 1.8-fold higher than the frequencies for dicentrics at a given dose. The dose-response curves for translocations and dicentrics were linear quadratic with a significant higher quadratic component for translocations. The application of FISH for scoring stable translocations for biological dosimetry of radiation exposures is discussed.
Collapse
Affiliation(s)
- E Schmid
- Institut für Strahlenbiologie, GSF-Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany
| | | | | | | | | |
Collapse
|
11
|
Abstract
Comparative Genomic Hybridization (CGH) is a powerful molecular cytogenetic technique that permits assessment of DNA copy number on a genome-wide scale. Of note, this methodology uses tumor DNA as a probe for fluorescence in situ hybridization (FISH) to normal metaphase chromosomes and does not require dividing cells from the tumor specimen. This unit provides protocols for CGH, for preparation of metaphase chromosomes, tumor and normal DNAs for FISH and for the microscopy and image analysis of CGH experiments.
Collapse
Affiliation(s)
- S DeVries
- University of California at San Francisco, San Francisco, USA
| | | | | | | | | |
Collapse
|
12
|
Gray JW, Das D, Wang N, Kuo W, Press MF, Di Leo A, Ellis C, Arbushites M, Williams L, Koehler M. Identification of a 6 gene molecular predictor of lapatinib related benefit: From breast cancer cell lines to a phase III trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Abstract
Meticillin-resistant Staphylococcus aureus (MRSA) isolates from children presenting to Birmingham hospitals were characterized using molecular methods. The study was performed on MRSA isolates from children aged </=16 years, identified between March 2004 and December 2004, from three hospitals offering general paediatric services. Fifty isolates were classified as either community-acquired (CA-MRSA) or hospital-acquired MRSA (HA-MRSA) according to Centers for Disease Control and Prevention (CDC) criteria. They underwent susceptibility testing and pulsed-field gel electrophoresis (PFGE) analyses. Polymerase chain reaction (PCR) methodology was used to determine the type of staphylococcal chromosome cassette (SCCmec) and the presence or absence of genes encoding Panton-Valentine leucocidin (PVL). Overall, 31 (62%) MRSA were defined as CA-MRSA. PFGE band pattern and SCCmec analysis were similar to EMRSA 15 for 72% of isolates. Over 80% of isolates contained SCCmec type IV; one isolate was untypable. Genes encoding PVL were not detected. MRSA in children presenting to Birmingham hospitals classified as CA-MRSA are most likely to resemble the usual hospital epidemic strains. None of the isolates fulfilled the criteria for de-novo CA-MRSA based on PFGE, PVL production and SCCmec analysis.
Collapse
Affiliation(s)
- A Adedeji
- Department of Microbiology, Birmingham Children's Hospital, Birmingham, UK.
| | | | | |
Collapse
|
14
|
Abstract
BACKGROUND Representational oligonucleotide microarray analysis has been developed for detection of single nucleotide polymorphisms and/or for genome copy number changes. In this process, the intensity of hybridization to oligonucleotides arrays is increased by hybridizing a polymerase chain reaction (PCR)-amplified representation of reduced genomic complexity. However, hybridization to some oligonucleotides is not sufficiently high to allow precise analysis of that portion of the genome. METHODS In an effort to identify aspects of oligonucleotide hybridization affecting signal intensity, we explored the importance of the PCR product strand to which each oligonucleotide is homologous and the sequence of the array oligonucleotides. We accomplished this by hybridizing multiple PCR-amplified products to oligonucleotide arrays carrying two sense and two antisense 50-mer oligonucleotides for each PCR amplicon. RESULTS In some cases, hybridization intensity depended more strongly on the PCR amplicon strand (i.e., sense vs. antisense) than on the detection oligonucleotide sequence. In other cases, the oligonucleotide sequence seemed to dominate. CONCLUSION Oligonucleotide arrays for analysis of DNA copy number or for single nucleotide polymorphism content should be designed to carry probes to sense and antisense strands of each PCR amplicon to ensure sufficient hybridization and signal intensity.
Collapse
Affiliation(s)
- R A Baldocchi
- University of California at San Francisco Cancer Center, San Francisco, California, USA.
| | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
AIMS To investigate the epidemiological and clinical aspects of MRSA among inpatients and outpatients presenting to hospital. METHODS Analysis of demographic, epidemiological, and clinical data collected on 385 children first identified as having MRSA between January 1998 and December 2003 in a 250 bed English children's hospital. RESULTS There were 267 inpatients and 118 outpatients. The number of new cases of MRSA declined from 72 in 1998 to 52 in 2003, whereas hospital activity increased. Ninety nine (37.1%) inpatients acquired MRSA outside the hospital; a further 90 occurred among 31 clusters of cases. One hundred and seventy eight (66.7%) inpatients were aged <2 years; cardiac services and paediatric & neonatal surgery accounted for 59.6% of cases. Dermatology and A&E accounted for 51.7% of outpatients; 73.8% of outpatients had recently previously attended the hospital. A total of 13.9% of inpatients with MRSA developed bacteraemia; MRSA accounted for 15% of Staphylococcus aureus bacteraemias. The risk of MRSA bacteraemia in colonised patients, and the proportion of S aureus bacteraemias that were MRSA, varied between specialties. Intravascular devices were the most common source of MRSA bacteraemia (63.4% of cases). The mortality rate was 7.3%. CONCLUSIONS Enhanced surveillance of MRSA can identify at-risk patient groups, thus facilitating targeting of control measures. The absence of a link between numbers of cases of acquisition of MRSA and bacteraemia suggests that the rise in MRSA bacteraemia may not solely reflect an increase in MRSA prevalence in children in the UK. The need for larger epidemiological studies is emphasised.
Collapse
Affiliation(s)
- A Adedeji
- Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.
| | | |
Collapse
|
16
|
Chin K, Devries S, Fridlyand J, Spellman P, Kuo WL, Lapuk A, Neve R, Tokuyasu T, Kingsley C, Dairkee S, Chew K, Jain A, Ljung BM, Esserman L, Waldman F, Gray JW. Genomic and transcriptional events associated with poor clinical responses to conventional therapies. Breast Cancer Res 2005. [PMCID: PMC4233480 DOI: 10.1186/bcr1059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
17
|
Abstract
Chickenpox is generally a benign childhood disease. Bacterial superinfection is the commonest complication, and can be severe and life-threatening. We describe a 15-year-old boy with disseminated Staphylococcus aureus infection following chickenpox.
Collapse
Affiliation(s)
- R J Raja Lope
- Department of Paediatrics, Birmingham Children's Hospital, Ladywood Middleway, Birmingham. UK.
| | | | | |
Collapse
|
18
|
Affiliation(s)
- J W Gray
- Department of Microbiology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.
| |
Collapse
|
19
|
Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, Hanahan D, Gray JW. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 2001; 29:459-64. [PMID: 11694878 DOI: 10.1038/ng771] [Citation(s) in RCA: 230] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Carcinomas that develop in the pancreatic islets of transgenic mice expressing the SV40 T-antigens (Tag) under transcriptional control of the rat insulin II promoter (RIP) progress through well-characterized stages that are similar to aspects of human tumor progression, including hyperplastic growth, increased angiogenesis and reduced apoptosis. The latter two stages have been associated with recurrent loss of heterozygosity (LOH) and reduced genome copy number on chromosomes 9 (LOH9) and 16 (LOH16), aberrations which we believe contribute to these phenotypes. Earlier analyses localized LOH9 to approximately 3 Mb and LOH16 to approximately 30 Mb (both syntenic with human 3q21-q25) but were limited by low throughput and a lack of informative polymorphic markers. Here we show that comparative genomic hybridization to DNA microarrays (array CGH) overcomes these limitations by allowing efficient, genome-wide analyses of relative genome copy number. The CGH arrays used in these experiments carried BACs distributed at 2-20-MB intervals across the mouse genome and at higher density in regions of interest. Using array CGH, we further narrowed the loci for LOH9 and LOH16 and defined new or previously unappreciated recurrent regions of copy-number decrease on chromosomes 6, 8 and 14 (syntenic with human chromosomes 12p11-p13, 16q24.3 and 13q11-q32, respectively) and regions of copy-number increase on chromosomes 2 and 4 (syntenic to human chromosomes 20q13.2 and 1p32-p36, respectively). Our analyses of human genome sequences syntenic to these regions suggest that CYP24, PFDN4, STMN1, CDKN1B, PPP2R3 and FSTL1 are candidate oncogenes or tumor-suppressor genes. We also show that irradiation and genetic background influence the spectrum of aberrations present in these tumors.
Collapse
Affiliation(s)
- G Hodgson
- Cancer Genetics and Breast Oncology Programs, UCSF Cancer Center, University of California at San Francisco, Box 0808, San Francisco, California 94143-0808, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, Albertson DG. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001; 29:263-4. [PMID: 11687795 DOI: 10.1038/ng754] [Citation(s) in RCA: 695] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We have assembled arrays of approximately 2,400 BAC clones for measurement of DNA copy number across the human genome. The arrays provide precise measurement (s.d. of log2 ratios=0.05-0.10) in cell lines and clinical material, so that we can reliably detect and quantify high-level amplifications and single-copy alterations in diploid, polyploid and heterogeneous backgrounds.
Collapse
Affiliation(s)
- A M Snijders
- Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
|
22
|
Jain AN, Chin K, Børresen-Dale AL, Erikstein BK, Eynstein Lonning P, Kaaresen R, Gray JW. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci U S A 2001; 98:7952-7. [PMID: 11438741 PMCID: PMC35449 DOI: 10.1073/pnas.151241198] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
We present a general method for rigorously identifying correlations between variations in large-scale molecular profiles and outcomes and apply it to chromosomal comparative genomic hybridization data from a set of 52 breast tumors. We identify two loci where copy number abnormalities are correlated with poor survival outcome (gain at 8q24 and loss at 9q13). We also identify a relationship between abnormalities at two loci and the mutational status of p53. Gain at 8q24 and loss at 5q15-5q21 are linked with mutant p53. The 9q and 5q losses suggest the possibility of gene products involved in breast cancer progression. The analytical techniques are general and also are applicable to the analysis of array-based expression data.
Collapse
Affiliation(s)
- A N Jain
- UCSF Cancer Center, University of California, San Francisco, Box 0128, San Francisco, CA 94143-0128, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Collins C, Volik S, Kowbel D, Ginzinger D, Ylstra B, Cloutier T, Hawkins T, Predki P, Martin C, Wernick M, Kuo WL, Alberts A, Gray JW. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res 2001; 11:1034-42. [PMID: 11381030 PMCID: PMC311107 DOI: 10.1101/gr.gr1743r] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Gene amplification occurs in most solid tumors and is associated with poor prognosis. Amplification of 20q13.2 is common to several tumor types including breast cancer. The 1 Mb of sequence spanning the 20q13.2 breast cancer amplicon is one of the most exhaustively studied segments of the human genome. These studies have included amplicon mapping by comparative genomic hybridization (CGH), fluorescent in-situ hybridization (FISH), array-CGH, quantitative microsatellite analysis (QUMA), and functional genomic studies. Together these studies revealed a complex amplicon structure suggesting the presence of at least two driver genes in some tumors. One of these, ZNF217, is capable of immortalizing human mammary epithelial cells (HMEC) when overexpressed. In addition, we now report the sequencing of this region in human and mouse, and on quantitative expression studies in tumors. Amplicon localization now is straightforward and the availability of human and mouse genomic sequence facilitates their functional analysis. However, comprehensive annotation of megabase-scale regions requires integration of vast amounts of information. We present a system for integrative analysis and demonstrate its utility on 1.2 Mb of sequence spanning the 20q13.2 breast cancer amplicon and 865 kb of syntenic murine sequence. We integrate tumor genome copy number measurements with exhaustive genome landscape mapping, showing that amplicon boundaries are associated with maxima in repetitive element density and a region of evolutionary instability. This integration of comprehensive sequence annotation, quantitative expression analysis, and tumor amplicon boundaries provide evidence for an additional driver gene prefoldin 4 (PFDN4), coregulated genes, conserved noncoding regions, and associate repetitive elements with regions of genomic instability at this locus.
Collapse
Affiliation(s)
- C Collins
- University of California San Francisco Cancer Center, San Francisco, California 94143-0808, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Parrott JA, Nilsson E, Mosher R, Magrane G, Albertson D, Pinkel D, Gray JW, Skinner MK. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol 2001; 175:29-39. [PMID: 11325514 DOI: 10.1016/s0303-7207(01)00436-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Stromal cells are essential for the progression of many cancers including ovarian tumors. Stromal cell-epithelial cell interactions are important for tumor development, growth, angiogenesis, and metastasis. In the current study, the effects of normal ovarian bovine stromal cells on ovarian tumor progression was investigated. The hypothesis tested is that ovarian stromal cells will alter the onset and progression of ovarian tumors. Conditioned medium from normal bovine ovarian surface stromal cells was found to stimulate the growth of normal ovarian surface epithelium and had no effect on the growth of human tumor cell lines SKOV3 and OCC1. Human ovarian cancer cell lines, SKOV3 and OCC1, were injected subcutaneously into nude mice to examine tumor progression. Tumor growth in the nude mice was dramatically reduced when normal ovarian surface stromal cells were co-injected with SKOV3 or OCC1 cells. Similar results were obtained with normal bovine or human ovarian stromal cells. In contrast, irrelevant testicular stromal cells and epithelial cells had no effect on tumor growth in the nude mouse. Histological examination of these tumors revealed a characteristic stromal cell component adjacent to epithelial cell colonies. Sections of these tumors were hybridized with species specific genomic probes using fluorescence in situ hybridization to identify cell populations. Epithelial cells were shown to be of human origin (i.e. SKOV3 or OCC1), but stromal cells were found to be primarily murine in origin (i.e. host tissue). No detectable bovine cells were observed in the tumors after one week post-injection. Results suggest that stromal cells are an essential component of ovarian tumors. Interestingly, normal ovarian stromal cells had the ability to inhibit tumor growth, but were not able to survive long-term incubation at the tumor site. The developing tumor appears to recruit host (i.e. murine) stromal cells to invade the tumor and support its growth. In summary, normal ovarian stromal cells can inhibit ovarian tumor progression and the developing tumors recruit adjacent host stroma to become "tumor stroma". The tumor stroma likely develop an altered phenotype that cooperates with the tumorigenic epithelial cells to help promote the progression of ovarian cancer.
Collapse
Affiliation(s)
- J A Parrott
- Center for Reproductive Biology, School of Molecular Biosciences, Washington State University, Pullman, WA 99164-4231, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW, Jensen RH. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2001; 2:84-91. [PMID: 11272893 PMCID: PMC1906896 DOI: 10.1016/s1525-1578(10)60621-6] [Citation(s) in RCA: 257] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Analysis of gene expression and correlation with clinical parameters has the potential to become an important factor in therapeutic decision making. The ability to analyze gene expression in archived tissues, for which clinical followup is already available, will greatly facilitate research in this area. A major obstacle to this approach, however, has been the uncertainty about whether gene expression analyses from routinely archived tissues accurately reflect expression before fixation. In the present study we have optimized the RNA isolation and reverse transcription steps for quantitative reverse transcription-polymerase chain reaction (RT-PCR) on archival material. Using tissue taken directly from the operating room, mRNAs with half-lives from 10 minutes to >8 hours were isolated and reverse transcribed. Subsequent real-time quantitative PCR methodology (TaqMan) on these cDNAs gives a measurement of gene expression in the fixed tissues comparable to that in the fresh tissue. In addition, we simulated routine pathology handling and demonstrate that this method of mRNA quantitation is insensitive to pre-fixation times (time from excision to fixation) of up to 12 hours. Therefore, it should be feasible to analyze gene expression in archived tissues where tissue collection procedures are largely unknown.
Collapse
Affiliation(s)
- T E Godfrey
- Department of Laboratory Medicine, University of California San Francisco Cancer Center, USA.
| | | | | | | | | | | | | |
Collapse
|
26
|
Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001; 61:1250-4. [PMID: 11245413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The functional consequences of overexpression of a candidate oncogene on chromosome 20q13.2, ZNF217, were examined by transducing the gene into finite life span human mammary epithelial cells (HMECs). In four independent experiments, ZNF217-transduced cultures gave rise to immortalized cells. HMECs that overcame senescence initially exhibited heterogeneous growth and continued telomere erosion, followed by increasing telomerase activity, stabilization of telomere length, and resistance to transforming growth factor beta growth inhibition. The incremental changes in telomerase activity and growth that occurred in ZNF217-transduced cultures after they overcame senescence were similar to the conversion pattern we have described previously in rare HMEC lines immortalized after exposure to a chemical carcinogen. Aberrant expression of ZNF217 may be selected for during breast cancer progression because it allows breast cells to overcome senescence and attain immortality.
Collapse
Affiliation(s)
- G H Nonet
- Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | | | | | | |
Collapse
|
27
|
BAC Resource Consortium T, Cheung VG, Nowak N, Jang W, Kirsch IR, Zhao S, Chen XN, Furey TS, Kim UJ, Kuo WL, Olivier M, Conroy J, Kasprzyk A, Massa H, Yonescu R, Sait S, Thoreen C, Snijders A, Lemyre E, Bailey JA, Bruzel A, Burrill WD, Clegg SM, Collins S, Dhami P, Friedman C, Han CS, Herrick S, Lee J, Ligon AH, Lowry S, Morley M, Narasimhan S, Osoegawa K, Peng Z, Plajzer-Frick I, Quade BJ, Scott D, Sirotkin K, Thorpe AA, Gray JW, Hudson J, Pinkel D, Ried T, Rowen L, Shen-Ong GL, Strausberg RL, Birney E, Callen DF, Cheng JF, Cox DR, Doggett NA, Carter NP, Eichler EE, Haussler D, Korenberg JR, Morton CC, Albertson D, Schuler G, de Jong PJ, Trask BJ. Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature 2001; 409:953-8. [PMID: 11237021 PMCID: PMC7845515 DOI: 10.1038/35057192] [Citation(s) in RCA: 203] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We have placed 7,600 cytogenetically defined landmarks on the draft sequence of the human genome to help with the characterization of genes altered by gross chromosomal aberrations that cause human disease. The landmarks are large-insert clones mapped to chromosome bands by fluorescence in situ hybridization. Each clone contains a sequence tag that is positioned on the genomic sequence. This genome-wide set of sequence-anchored clones allows structural and functional analyses of the genome. This resource represents the first comprehensive integration of cytogenetic, radiation hybrid, linkage and sequence maps of the human genome; provides an independent validation of the sequence map and framework for contig order and orientation; surveys the genome for large-scale duplications, which are likely to require special attention during sequence assembly; and allows a stringent assessment of sequence differences between the dark and light bands of chromosomes. It also provides insight into large-scale chromatin structure and the evolution of chromosomes and gene families and will accelerate our understanding of the molecular bases of human disease and cancer.
Collapse
Affiliation(s)
| | - V. G. Cheung
- grid.239552.a0000 0001 0680 8770Department of Pediatrics, University of Pennsylvania, The Children's Hospital of Philadelphia, 3516 Civic Center Boulevard, ARC 516, Philadelphia, 19104 Pennsylvania USA
| | - N. Nowak
- grid.240614.50000 0001 2181 8635Roswell Park Cancer Institute, Elm and Carleton Street, Buffalo, 14263 New York USA
| | - W. Jang
- grid.419234.90000 0004 0604 5429National Center for Biotechnology Information, National Library of Medicine, Building 38A/Room 8N805, Bethesda, 20894 Maryland USA
| | - I. R. Kirsch
- grid.420086.80000 0001 2237 2479National Cancer Institute, NIH, Building 10/Room 12N214, Bethesda, 20889-5105 Maryland USA
| | - S. Zhao
- grid.469946.0The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, 20850 Maryland USA
| | - X.-N. Chen
- grid.50956.3f0000 0001 2152 9905Departments of Pediatrics and Human Genetics, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, 90048 California USA
| | - T. S. Furey
- grid.205975.c0000 0001 0740 6917Computer Science Department, University of California Santa Cruz, 1156 High Street, Santa Cruz, 95064-1077 California USA
| | - U.-J. Kim
- grid.20861.3d0000000107068890Department of Biology, California Institute of Technology, Mail Code 147-75, Pasadena, 91125 California USA ,Present Address: PanGenomics, 6401 Foothill Boulevard, Tujunga, California 91024 USA
| | - W.-L. Kuo
- grid.266102.10000 0001 2297 6811University of California San Francisco Cancer Center, Box 0808, San Francisco, 94143-0808 California USA
| | - M. Olivier
- grid.168010.e0000000419368956Stanford University, Genome Lab, Mail Code 5120, Stanford, 94305-5120 California USA
| | - J. Conroy
- grid.240614.50000 0001 2181 8635Roswell Park Cancer Institute, Elm and Carleton Street, Buffalo, 14263 New York USA
| | - A. Kasprzyk
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - H. Massa
- grid.270240.30000 0001 2180 1622Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North C3-168, P.O. Box 19024, Seattle, 98109-1024 Washington USA
| | - R. Yonescu
- grid.420086.80000 0001 2237 2479National Cancer Institute, NIH, Building 10/Room 12N214, Bethesda, 20889-5105 Maryland USA
| | - S. Sait
- grid.240614.50000 0001 2181 8635Roswell Park Cancer Institute, Elm and Carleton Street, Buffalo, 14263 New York USA
| | - C. Thoreen
- grid.34477.330000000122986657Department of Molecular Biotechnology, University of Washington, Box 357730, Seattle, 98195-7730 Washington USA ,grid.38142.3c000000041936754XPresent Address: Harvard Medical School, Cell Biology, 240 Longwood Avenue, Cambridge, Massachusetts 02115 USA
| | - A. Snijders
- grid.266102.10000 0001 2297 6811University of California San Francisco Cancer Center, Box 0808, San Francisco, 94143-0808 California USA
| | - E. Lemyre
- grid.62560.370000 0004 0378 8294Departments of Obstetrics and Gynecology and Pathology, Brigham and Women's Hospital, Amory Lab Building 3rd floor, Boston, 02115 Massachusetts USA
| | - J. A. Bailey
- grid.67105.350000 0001 2164 3847Department of Human Genetics, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, 44106 Ohio USA
| | - A. Bruzel
- grid.239552.a0000 0001 0680 8770Department of Pediatrics, University of Pennsylvania, The Children's Hospital of Philadelphia, 3516 Civic Center Boulevard, ARC 516, Philadelphia, 19104 Pennsylvania USA
| | - W. D. Burrill
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - S. M. Clegg
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - S. Collins
- grid.34477.330000000122986657Department of Molecular Biotechnology, University of Washington, Box 357730, Seattle, 98195-7730 Washington USA
| | - P. Dhami
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - C. Friedman
- grid.270240.30000 0001 2180 1622Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North C3-168, P.O. Box 19024, Seattle, 98109-1024 Washington USA
| | - C. S. Han
- grid.148313.c0000 0004 0428 3079Joint Genome Institute-Los Alamos National Laboratory, MS M888 B-N1, P.O. Box 1663, Los Alamos, 87545 New Mexico USA
| | - S. Herrick
- grid.62560.370000 0004 0378 8294Departments of Obstetrics and Gynecology and Pathology, Brigham and Women's Hospital, Amory Lab Building 3rd floor, Boston, 02115 Massachusetts USA
| | - J. Lee
- grid.20861.3d0000000107068890Department of Biology, California Institute of Technology, Mail Code 147-75, Pasadena, 91125 California USA
| | - A. H. Ligon
- grid.62560.370000 0004 0378 8294Departments of Obstetrics and Gynecology and Pathology, Brigham and Women's Hospital, Amory Lab Building 3rd floor, Boston, 02115 Massachusetts USA
| | - S. Lowry
- grid.184769.50000 0001 2231 4551Joint Genome Institute-Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Mail Stop 84-171, Berkeley, 94720 California USA
| | - M. Morley
- grid.239552.a0000 0001 0680 8770Department of Pediatrics, University of Pennsylvania, The Children's Hospital of Philadelphia, 3516 Civic Center Boulevard, ARC 516, Philadelphia, 19104 Pennsylvania USA
| | - S. Narasimhan
- grid.239552.a0000 0001 0680 8770Department of Pediatrics, University of Pennsylvania, The Children's Hospital of Philadelphia, 3516 Civic Center Boulevard, ARC 516, Philadelphia, 19104 Pennsylvania USA
| | - K. Osoegawa
- grid.240614.50000 0001 2181 8635Roswell Park Cancer Institute, Elm and Carleton Street, Buffalo, 14263 New York USA ,grid.414016.60000 0004 0433 7727Children's Hospital Oakland Research Institute, 747 52nd Street, Oakland, 94609 California USA
| | - Z. Peng
- grid.184769.50000 0001 2231 4551Joint Genome Institute-Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Mail Stop 84-171, Berkeley, 94720 California USA
| | - I. Plajzer-Frick
- grid.184769.50000 0001 2231 4551Joint Genome Institute-Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Mail Stop 84-171, Berkeley, 94720 California USA
| | - B. J. Quade
- grid.62560.370000 0004 0378 8294Departments of Obstetrics and Gynecology and Pathology, Brigham and Women's Hospital, Amory Lab Building 3rd floor, Boston, 02115 Massachusetts USA
| | - D. Scott
- grid.184769.50000 0001 2231 4551Joint Genome Institute-Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Mail Stop 84-171, Berkeley, 94720 California USA
| | - K. Sirotkin
- grid.419234.90000 0004 0604 5429National Center for Biotechnology Information, National Library of Medicine, Building 38A/Room 8N805, Bethesda, 20894 Maryland USA
| | - A. A. Thorpe
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - J. W. Gray
- grid.266102.10000 0001 2297 6811University of California San Francisco Cancer Center, Box 0808, San Francisco, 94143-0808 California USA
| | - J. Hudson
- grid.418190.50000 0001 2187 0556Research Genetics, 2130 Memorial Parkway, Huntsville, 35801 Alabama USA
| | - D. Pinkel
- grid.266102.10000 0001 2297 6811University of California San Francisco Cancer Center, Box 0808, San Francisco, 94143-0808 California USA
| | - T. Ried
- grid.420086.80000 0001 2237 2479National Cancer Institute, NIH, Building 10/Room 12N214, Bethesda, 20889-5105 Maryland USA
| | - L. Rowen
- grid.64212.330000 0004 0463 2320Institute for Systems Biology, 4225 Roosevelt Way NE, Suite 200, Seattle, 98105-6099 Washington USA
| | - G. L. Shen-Ong
- grid.420086.80000 0001 2237 2479National Cancer Institute, NIH, Building 10/Room 12N214, Bethesda, 20889-5105 Maryland USA ,Present Address: Gene Logic, Inc., 708 Quince Orchard Road, Gaithersburg, Maryland 20878 USA
| | - R. L. Strausberg
- grid.420086.80000 0001 2237 2479National Cancer Institute, NIH, Building 10/Room 12N214, Bethesda, 20889-5105 Maryland USA
| | - E. Birney
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - D. F. Callen
- grid.1694.aDepartment of Cytogenetics and Molecular Genetics, Women's and Children's Hospital, 72 King William Road, North Adelaide, 5006 South Australia Australia
| | - J.-F. Cheng
- grid.184769.50000 0001 2231 4551Joint Genome Institute-Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Mail Stop 84-171, Berkeley, 94720 California USA
| | - D. R. Cox
- grid.168010.e0000000419368956Stanford University, Genome Lab, Mail Code 5120, Stanford, 94305-5120 California USA
| | - N. A. Doggett
- grid.148313.c0000 0004 0428 3079Joint Genome Institute-Los Alamos National Laboratory, MS M888 B-N1, P.O. Box 1663, Los Alamos, 87545 New Mexico USA
| | - N. P. Carter
- Sanger Center, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge UK
| | - E. E. Eichler
- grid.67105.350000 0001 2164 3847Department of Human Genetics, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, 44106 Ohio USA
| | - D. Haussler
- grid.205975.c0000 0001 0740 6917Computer Science Department, Howard Hughes Medical Institute, University of California Santa Cruz, 1156 High Street, Santa Cruz, 95064–1077 California USA
| | - J. R. Korenberg
- grid.50956.3f0000 0001 2152 9905Departments of Pediatrics and Human Genetics, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, 90048 California USA
| | - C. C. Morton
- grid.62560.370000 0004 0378 8294Departments of Obstetrics and Gynecology and Pathology, Brigham and Women's Hospital, Amory Lab Building 3rd floor, Boston, 02115 Massachusetts USA
| | - D. Albertson
- grid.266102.10000 0001 2297 6811University of California San Francisco Cancer Center, Box 0808, San Francisco, 94143-0808 California USA
| | - G. Schuler
- grid.419234.90000 0004 0604 5429National Center for Biotechnology Information, National Library of Medicine, Building 38A/Room 8N805, Bethesda, 20894 Maryland USA
| | - P. J. de Jong
- grid.240614.50000 0001 2181 8635Roswell Park Cancer Institute, Elm and Carleton Street, Buffalo, 14263 New York USA ,grid.414016.60000 0004 0433 7727Children's Hospital Oakland Research Institute, 747 52nd Street, Oakland, 94609 California USA
| | - B. J. Trask
- grid.270240.30000 0001 2180 1622Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North C3-168, P.O. Box 19024, Seattle, 98109-1024 Washington USA
| |
Collapse
|
28
|
Ginzinger DG, Godfrey TE, Nigro J, Moore DH, Suzuki S, Pallavicini MG, Gray JW, Jensen RH. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 2000; 60:5405-9. [PMID: 11034080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
This report describes the development and validation of quantitative microsatellite analysis (QuMA) for rapid measurement of relative DNA sequence copy number. In QuMA, the copy number of a test locus relative to a pooled reference is assessed using quantitative, real-time PCR amplification of loci carrying simple sequence repeats. Use of simple sequence repeats is advantageous because of the large numbers that are mapped precisely. In addition, all markers are informative because QuMA does not require that they be polymorphic. The utility of QuMA is demonstrated in assessment of the extent of deletions of chromosome 2 in leukemias arising in radiation-sensitive inbred SJL mice and in analysis of the association of increased copy number of the putative oncogene ZNF217 with reduced survival duration in ovarian cancer patients.
Collapse
Affiliation(s)
- D G Ginzinger
- Department of Laboratory Medicine, University of California San Francisco Comprehensive Cancer Center, University of California, 94143, USA
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Suzuki S, Moore DH, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000; 60:5382-5. [PMID: 11034075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
This report describes analyses of associations of genome copy number abnormalities in ovarian cancers with clinical features using genome-wide graphical and analytical procedures. These studies show that tumor grade is a better indicator of the extent of genomic progression than stage, that loss of chromosome 4 occurs preferentially in high-grade tumors, and that gains of 3q26-qter, 8q24-qter, and 20q13-qter occur frequently in low-grade and low-stage tumors and thus may be early events in ovarian cancer development. In addition, loss of chromosome 16q24 and a total number of independent genome copy number aberrations >7 are associated with reduced survival duration. The association of loss of 16q24 (D16S3026) with decreased survival duration was confirmed by quantitative PCR. Regions that frequently are abnormal and associated with altered survival duration are strong candidates for higher resolution analysis and gene discovery and may be useful markers for prediction of clinical outcome.
Collapse
Affiliation(s)
- S Suzuki
- Cancer Center, University of California, San Francisco, 94143-0808, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
In our previous work, we had characterized ARHI as an imprinted putative tumor-suppressor gene in ovarian and breast cancers. ARHI is expressed in primary breast and ovarian cell lines but largely absent from the corresponding malignant tumors. Moreover, the non-imprinted functional allele is typically deleted in malignant cells. Since ARHI had been mapped to 1p31, a common deletion site in breast and ovarian cancer and male germ-cell tumors, in this study, we set out to define precisely the physical location of ARHI at 1p31 and to determine if this location lies within the smallest common region of deletion in breast and ovarian cancers. To this end, we first carried out radiation hybrid mapping of ARHI and surrounding markers, followed by a high-resolution study of loss of heterozygosity at 1p31 in 49 ovarian and breast cancers. Combining a radiation hybrid map and a physical map of the region encompassing ARHI, 3 discrete regions of minimal deletion were found at 1p31 in breast and ovarian cancers. ARHI is the most common deletion region at 1p31. Two other less common regions of deletion were found centromeric to this gene. One of them centered on D1S207 and the other one included and was proximal to D1S488. We also confirmed the preferential loss of non-imprinted functional allele in 7 of 9 tumor specimens. These data support the possibility that ARHI is a tumor-suppressor gene and suggest that additional tumor-suppressor genes may lie proximal to ARHI at 1p31. The data obtained from our study should aid in the identification and characterization of genes in this novel imprinted region.
Collapse
Affiliation(s)
- H Peng
- Division of Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25:144-6. [PMID: 10835626 DOI: 10.1038/75985] [Citation(s) in RCA: 464] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We show here that quantitative measurement of DNA copy number across amplified regions using array comparative genomic hybridization (CGH) may facilitate oncogene identification by providing precise information on the locations of both amplicon boundaries and amplification maxima. Using this analytical capability, we resolved two regions of amplification within an approximately 2-Mb region of recurrent aberration at 20q13.2 in breast cancer. The putative oncogene ZNF217 (ref. 5) mapped to one peak, and CYP24 (encoding vitamin D 24 hydroxylase), whose overexpression is likely to lead to abrogation of growth control mediated by vitamin D, mapped to the other.
Collapse
Affiliation(s)
- D G Albertson
- [1] Cancer Research Institute, University of California, San Francisco, Box 0808, San Francisco, California, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Vancomycin resistant enterococci (VRE) are increasingly important nosocomial pathogens. This paper describes our experience of the epidemiology and clinical impact of VRE in the two years since the occurrence of our first case of VRE infection. Following introduction of surveillance, gastrointestinal colonization with VRE was detected in 38.3% of Haematology/Oncology and 11.1% of Hepatology/Gastroenterology patients, but in only 2.3% of children in the Paediatric Intensive Care and 1.5% of children in the Renal Unit. Only five patients with gastrointestinal colonization subsequently developed clinical infection with VRE, giving an annual incidence of 7.5%. A further six children were colonized at extra-intestinal sites. Twelve children had clinical infections with VRE, of whom three (25%) died. Contamination of bedspaces was found in association with 2/3 (66.7%) children with extraintestinal colonization and 5/7 (71.4%) children with clinical infections, compared with 6/28 (21.4%) cases of gastrointestinal colonization. In the latter group, bedspace contamination was usually associated with widespread contamination of the ward with VRE and may have been the cause rather than the result of patients acquiring VRE. Originally we employed control measures based closely on the North American HICPAC guidelines, but our control strategy has since evolved in response to epidemiological and clinical observations.
Collapse
Affiliation(s)
- J W Gray
- Department of Microbiology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH.
| | | |
Collapse
|
33
|
Abstract
Genome-wide analysis techniques such as chromosome painting, comparative genomic hybridization, representational difference analysis, restriction landmark genome scanning and high-throughput analysis of LOH are now accelerating high-resolution genome aberration localization in human tumors. These techniques are complemented by procedures for detection of differentially expressed genes such as differential display, nucleic acid subtraction, serial analysis of gene expression and expression microarray analysis. These efforts are enabled by work from the human genome program in physical map development, cDNA library production/sequencing and in genome sequencing. This review covers several commonly used large-scale genome and gene expression analysis techniques, outlines genomic approaches to gene discovery and summarizes information that has come from large-scale analyses of human solid tumors.
Collapse
Affiliation(s)
- J W Gray
- UCSF Cancer Center, 2340 Sutter Street, University of California San Francisco, San Francisco, CA 94143-0808, USA.
| | | |
Collapse
|
34
|
Gray JW, Darbyshire PJ, Beath SV, Kelly D, Mann JR. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children. Pediatr Infect Dis J 2000; 19:234-8. [PMID: 10749466 DOI: 10.1097/00006454-200003000-00012] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The emergence and spread of vancomycin-resistant Enterococcus faecium (VREF) has presented serious therapeutic difficulties because of the lack of reliably active antibiotics. Quinupristin/dalfopristin is a new injectable streptogramin antibiotic that is active against most strains of VREF. Experience with this agent in adults with VREF infections is well-documented; however, there are few reports of its use in children. We report on eight children with VREF infections who received quinupristin/dalfopristin under a compassionate use protocol. METHODS Quinupristin/dalfopristin was administered according to the manufacturer's recommendations. Clinical and laboratory data were recorded for each patient. RESULTS The infections treated comprised six cases of bacteremia and two of peritonitis. All patients had serious underlying conditions. Seven patients recovered fully. One patient died, having experienced a relapse of his infection after quinupristin/dalfopristin was discontinued. None of the patients experienced side effects or other adverse events. CONCLUSION Quinupristin/dalfopristin was well-tolerated and generally effective in children with infections caused by VREF. There is increasing evidence that it may be more effective than other currently available antibiotics in some such patients.
Collapse
Affiliation(s)
- J W Gray
- Department of Microbiology, Birmingham Children's Hospital, UK.
| | | | | | | | | |
Collapse
|
35
|
Frost GI, Mohapatra G, Wong TM, Csóka AB, Gray JW, Stern R. HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 2000; 19:870-7. [PMID: 10702795 DOI: 10.1038/sj.onc.1203317] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The hyaluronidase first isolated from human plasma, Hyal-1, is expressed in many somatic tissues. The Hyal-1 gene, HYAL1, also known as LUCA-1, maps to chromosome 3p21.3 within a candidate tumor suppressor gene locus defined by homozygous deletions and by functional tumor suppressor activity. Hemizygosity in this region occurs in many malignancies, including squamous cell carcinomas of the head and neck. We have investigated whether cell lines derived from such malignancies expressed Hyal-1 activity, using normal human keratinocytes as controls. Hyal-1 enzyme activity and protein were absent or markedly reduced in six of seven carcinoma cell lines examined. Comparative genomic and fluorescence in situ hybridization identified chromosomal deletions of one allele of HYAL1 in six of seven cell lines. Initial RT - PCR analyses demonstrated marked discrepancies between levels of HYAL1 mRNA and protein. Despite repeated sequence analyses, no mutations were found. However, two species of transcripts were identified when primers were used that included the 5' untranslated region. The predominant mRNA species did not correlate with protein translation and contained a retained intron. A second spliced form lacking this intron was found only in cell lines that produced Hyal-1 protein. Inactivation of HYAL1 in these tumor lines is a result of incomplete splicing of its pre-mRNA that appears to be epigenetic in nature. Oncogene (2000) 19, 870 - 877.
Collapse
MESH Headings
- Alternative Splicing/genetics
- Carcinoma, Squamous Cell/enzymology
- Carcinoma, Squamous Cell/genetics
- Cell Line
- Chromosomes, Human, Pair 3/genetics
- DNA, Complementary/genetics
- DNA, Complementary/isolation & purification
- Enzyme Induction/genetics
- Exons/genetics
- Gene Expression Regulation
- Gene Expression Regulation, Enzymologic
- Genes, Tumor Suppressor/genetics
- Head and Neck Neoplasms/enzymology
- Head and Neck Neoplasms/genetics
- Humans
- Hyaluronoglucosaminidase/genetics
- Introns/genetics
- Open Reading Frames/genetics
- Promoter Regions, Genetic/genetics
- RNA Precursors/genetics
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- G I Frost
- Department of Pathology, School of Medicine, University of California, San Francisco, California, CA 94143, USA
| | | | | | | | | | | |
Collapse
|
36
|
Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98:137-46. [PMID: 10428026 PMCID: PMC2853255 DOI: 10.1016/s0092-8674(00)81009-0] [Citation(s) in RCA: 682] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Matrix metalloproteinases (MMPs) are invariably upregulated in the stromal compartment of epithelial cancers and appear to promote invasion and metastasis. Here we report that phenotypically normal mammary epithelial cells with tetracycline-regulated expression of MMP3/stromelysin-1 (Str1) form epithelial glandular structures in vivo without Str1 but form invasive mesenchymal-like tumors with Str1. Once initiated, the tumors become independent of continued Str1 expression. Str1 also promotes spontaneous premalignant changes and malignant conversion in mammary glands of transgenic mice. These changes are blocked by coexpression of a TIMP1 transgene. The premalignant and malignant lesions have stereotyped genomic changes unlike those seen in other murine mammary cancer models. These data indicate that Str1 influences tumor initiation and alters neoplastic risk.
Collapse
Affiliation(s)
- M D Sternlicht
- Department of Anatomy, University of California, San Francisco 94143-0452, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Ortiz de Solórzano C, García Rodriguez E, Jones A, Pinkel D, Gray JW, Sudar D, Lockett SJ. Segmentation of confocal microscope images of cell nuclei in thick tissue sections. J Microsc 1999; 193:212-26. [PMID: 10199001 DOI: 10.1046/j.1365-2818.1999.00463.x] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Segmentation of intact cell nuclei from three-dimensional (3D) images of thick tissue sections is an important basic capability necessary for many biological research studies. However, segmentation is often difficult because of the tight clustering of nuclei in many specimen types. We present a 3D segmentation approach that combines the recognition capabilities of the human visual system with the efficiency of automatic image analysis algorithms. The approach first uses automatic algorithms to separate the 3D image into regions of fluorescence-stained nuclei and unstained background. This includes a novel step, based on the Hough transform and an automatic focusing algorithm to estimate the size of nuclei. Then, using an interactive display, each nuclear region is shown to the analyst, who classifies it as either an individual nucleus, a cluster of multiple nuclei, partial nucleus or debris. Next, automatic image analysis based on morphological reconstruction and the watershed algorithm divides clusters into smaller objects, which are reclassified by the analyst. Once no more clusters remain, the analyst indicates which partial nuclei should be joined to form complete nuclei. The approach was assessed by calculating the fraction of correctly segmented nuclei for a variety of tissue types: Caenorhabditis elegans embryos (839 correct out of a total of 848), normal human skin (343/362), benign human breast tissue (492/525), a human breast cancer cell line grown as a xenograft in mice (425/479) and invasive human breast carcinoma (260/335). Furthermore, due to the analyst's involvement in the segmentation process, it is always known which nuclei in a population are correctly segmented and which not, assuming that the analyst's visual judgement is correct.
Collapse
Affiliation(s)
- C Ortiz de Solórzano
- Ernest Orlando Lawrence Berkeley National Laboratory, University of California 94720, USA.
| | | | | | | | | | | | | |
Collapse
|
38
|
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999; 96:214-9. [PMID: 9874798 PMCID: PMC15119 DOI: 10.1073/pnas.96.1.214] [Citation(s) in RCA: 226] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/1998] [Indexed: 11/18/2022] Open
Abstract
Using differential display PCR, we have identified a gene [NOEY2, ARHI (designation by the Human Gene Nomenclature Committee)] with high homology to ras and rap that is expressed consistently in normal ovarian and breast epithelial cells but not in ovarian and breast cancers. Reexpression of NOEY2 through transfection suppresses clonogenic growth of breast and ovarian cancer cells. Growth suppression was associated with down-regulation of the cyclin D1 promoter activity and induction of p21(WAF1/CIP1). In an effort to identify mechanisms leading to NOEY2 silencing in cancer, we found that the gene is expressed monoallelically and is imprinted maternally. Loss of heterozygosity of the gene was detected in 41% of ovarian and breast cancers. In most of cancer samples with loss of heterozygosity, the nonimprinted functional allele was deleted. Thus, NOEY2 appears to be a putative imprinted tumor suppressor gene whose function is abrogated in ovarian and breast cancers.
Collapse
Affiliation(s)
- Y Yu
- Division of Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102. [PMID: 9916799 DOI: 10.1038/5042] [Citation(s) in RCA: 811] [Impact Index Per Article: 32.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian and others cancers contains PIK3CA, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3-kinase). The association between PIK3CA copy number and PI3-kinase activity makes PIK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with PI3-kinase mediated signalling. These include proliferation, glucose transport and catabolism, cell adhesion, apoptosis, RAS signalling and oncogenic transformation. In addition, downstream effectors of PI3-kinase, AKT1 and AKT2, have been found to be amplified or activated in human tumours, including ovarian cancer. We show here that PIK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PIK3CA transcription, p110alpha protein expression and PI3-kinase activity and that treatment with the PI3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PIK3CA is an oncogene that has an important role in ovarian cancer.
Collapse
Affiliation(s)
- L Shayesteh
- UCSF Cancer Center, University of California, San Francisco 941430-0808, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sakamoto M, Umayahara K, Sakamoto H, Kawasaki K, Suehiro Y, Kunugi T, Akiya T, Iwabuchi H, Sakunaga H, Muroya T, Kikuchi Y, Sugishita T, Tenjin Y, Gray JW, Tanaka T. [Cancer-associated gene abnormalities and chemosensitivity]. Gan To Kagaku Ryoho 1998; 25:1819-31. [PMID: 9797804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
One of the most important clinical issues in cancer chemotherapy is the presence of intrinsic resistance or the appearance of acquired resistance against chemotherapy. As for intrinsic resistance, we had to perform direct chemo-sensitivity testing, or had to rely on the knowledge empirically acquired from randomized clinical trials. However, molecular or genetic markers associated with chemo-sensitivity have been reported recently. For example, inactivation of p53 or GML gene has been reported to be associated with chemo-resistance. Overexpression of topo-isomerase I has been reported to be associated with chemo-sensitivity to Topo I inhibitor. Overexpression of Thymidine Phosphorylase has been found to be associated with chemo-sensitivity to prodrug of 5-FU. By checking the status of such chemo-sensitivity markers prior to chemotherapy, it would be possible to predict the chemotherapeutic effect and even the necessity of the chemotherapy in the near future. In this article, we review the chemo-sensitivity markers reported so far, and methodology contributing to the discovery of new chemo-sensitivity markers. As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH). Copy number decrease in Xp, and copy number increase in 19q were observed in 13, 12 out of 29 resistant cases (45, 41%) and zero, 1 out of 11 sensitive cases (0, 9%), suggesting that -Xp and +19q were likely to be a genetic event associated with intrinsic drug-resistance (p = 0.006, 0.05, respectively). This effort should contribute to the discovery of new chemo-sensitivity and resistance markers.
Collapse
Affiliation(s)
- M Sakamoto
- Dept. of Gynecology, Sasaki Institute Kyoundo Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-93. [PMID: 9771714 DOI: 10.1038/2496] [Citation(s) in RCA: 959] [Impact Index Per Article: 36.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The centrosomes are thought to maintain genomic stability through the establishment of bipolar spindles during cell division, ensuring equal segregation of replicated chromosomes to two daughter cells. Deregulated duplication and distribution of centrosomes have been implicated in chromosome segregation abnormalities, leading to aneuploidy seen in many cancer cell types. Here, we report that STK15 (also known as BTAK and aurora2), encoding a centrosome-associated kinase, is amplified and overexpressed in multiple human tumour cell types, and is involved in the induction of centrosome duplication-distribution abnormalities and aneuploidy in mammalian cells. STK15 amplification has been previously detected in breast tumour cell lines and in colon tumours; here, we report its amplification in approximately 12% of primary breast tumours, as well as in breast, ovarian, colon, prostate, neuroblastoma and cervical cancer cell lines. Additionally, high expression of STK15 mRNA was detected in tumour cell lines without evidence of gene amplification. Ectopic expression of STK15 in mouse NIH 3T3 cells led to the appearance of abnormal centrosome number (amplification) and transformation in vitro. Finally, overexpression of STK15 in near diploid human breast epithelial cells revealed similar centrosome abnormality, as well as induction of aneuploidy. These findings suggest that STK15 is a critical kinase-encoding gene, whose overexpression leads to centrosome amplification, chromosomal instability and transformation in mammalian cells.
Collapse
Affiliation(s)
- H Zhou
- Division of Pathology & Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20:207-11. [PMID: 9771718 DOI: 10.1038/2524] [Citation(s) in RCA: 1420] [Impact Index Per Article: 54.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Gene dosage variations occur in many diseases. In cancer, deletions and copy number increases contribute to alterations in the expression of tumour-suppressor genes and oncogenes, respectively. Developmental abnormalities, such as Down, Prader Willi, Angelman and Cri du Chat syndromes, result from gain or loss of one copy of a chromosome or chromosomal region. Thus, detection and mapping of copy number abnormalities provide an approach for associating aberrations with disease phenotype and for localizing critical genes. Comparative genomic hybridization (CGH) was developed for genome-wide analysis of DNA sequence copy number in a single experiment. In CGH, differentially labelled total genomic DNA from a 'test' and a 'reference' cell population are cohybridized to normal metaphase chromosomes, using blocking DNA to suppress signals from repetitive sequences. The resulting ratio of the fluorescence intensities at a location on the 'cytogenetic map', provided by the chromosomes, is approximately proportional to the ratio of the copy numbers of the corresponding DNA sequences in the test and reference genomes. CGH has been broadly applied to human and mouse malignancies. The use of metaphase chromosomes, however, limits detection of events involving small regions (of less than 20 Mb) of the genome, resolution of closely spaced aberrations and linking ratio changes to genomic/genetic markers. Therefore, more laborious locus-by-locus techniques have been required for higher resolution studies. Hybridization to an array of mapped sequences instead of metaphase chromosomes could overcome the limitations of conventional CGH (ref. 6) if adequate performance could be achieved. Copy number would be related to the test/reference fluorescence ratio on the array targets, and genomic resolution could be determined by the map distance between the targets, or by the length of the cloned DNA segments. We describe here our implementation of array CGH. We demonstrate its ability to measure copy number with high precision in the human genome, and to analyse clinical specimens by obtaining new information on chromosome 20 aberrations in breast cancer.
Collapse
Affiliation(s)
- D Pinkel
- Cancer Genetics Program, UCSF Cancer Center, University of California San Francisco, 94143-0808, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, Cloutier T, Kuo WL, Yaswen P, Dairkee S, Giovanola J, Hutchinson GB, Isola J, Kallioniemi OP, Palazzolo M, Martin C, Ericsson C, Pinkel D, Albertson D, Li WB, Gray JW. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 1998; 95:8703-8. [PMID: 9671742 PMCID: PMC21140 DOI: 10.1073/pnas.95.15.8703] [Citation(s) in RCA: 233] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/1998] [Indexed: 02/08/2023] Open
Abstract
We report here the molecular cloning of an approximately 1-Mb region of recurrent amplification at 20q13.2 in breast cancer and other tumors and the delineation of a 260-kb common region of amplification. Analysis of the 1-Mb region produced evidence for five genes, ZNF217, ZNF218, and NABC1, PIC1L (PIC1-like), CYP24, and a pseudogene CRP (Cyclophillin Related Pseudogene). ZNF217 and NABC1 emerged as strong candidate oncogenes and were characterized in detail. NABC1 is predicted to encode a 585-aa protein of unknown function and is overexpressed in most but not all breast cancer cell lines in which it was amplified. ZNF217 is centrally located in the 260-kb common region of amplification, transcribed in multiple normal tissues, and overexpressed in all cell lines and tumors in which it is amplified and in two in which it is not. ZNF217 is predicted to encode alternately spliced, Kruppel-like transcription factors of 1,062 and 1,108 aa, each having a DNA-binding domain (eight C2H2 zinc fingers) and a proline-rich transcription activation domain.
Collapse
Affiliation(s)
- C Collins
- Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Studies using comparative genomic hybridization (CGH) indicate that portions of chromosome arm 8q from 8q12 to 8qter are present at an increased relative copy number in a broad range of solid tumors. In this study we define an approximately 1 Mb wide region that appears to be frequently abnormal in copy number or structure in breast cancer cell lines and primary tumors. This was accomplished by fluorescence in situ hybridization (FISH) with yeast artificial chromosomes (YACs) mapped to 8q2-q22. Eleven breast cancer cell lines and ten primary tumors were analyzed. A minimal region of rearrangement was localized to the CEPH-YAC 928F9 in three breast cancer cell lines with unbalanced translocation breakpoints mapping in this region. Unbalanced translocations also were detected in two primary tumors mapping between CEPH-YAC clones 890C4 and 936B3, flanking 928F9. An increased copy number in the minimal region was detected in nine cell lines and in multiple primary tumors. This suggests the possibility that a single gene mapping to 928F9 is involved in breast cancer development or progression and may be deregulated by copy number increases in some tumors and by translocation in others. Four expressed sequence tags were mapped to YAC 928F9 and analyzed for rearrangements by Southern analysis and for abnormal expression by Northern analysis.
Collapse
Affiliation(s)
- M S Fejzo
- UCSF Cancer Center, University of California, San Francisco 94115, USA
| | | | | | | | | |
Collapse
|
45
|
Lucito R, Nakimura M, West JA, Han Y, Chin K, Jensen K, McCombie R, Gray JW, Wigler M. Genetic analysis using genomic representations. Proc Natl Acad Sci U S A 1998; 95:4487-92. [PMID: 9539764 PMCID: PMC22516 DOI: 10.1073/pnas.95.8.4487] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Analysis of the genetic changes in human tumors is often problematical because of the presence of normal stroma and the limited availability of pure tumor DNA. However, large amounts of highly reproducible "representations" of tumor and normal genomes can be made by PCR from nanogram amounts of restriction endonuclease cleaved DNA that has been ligated to oligonucleotide adaptors. We show here that representations are useful for many types of genetic analyses, including measuring relative gene copy number, loss of heterozygosity, and comparative genomic hybridization. Representations may be prepared even from sorted nuclei from fixed and archived tumor biopsies.
Collapse
Affiliation(s)
- R Lucito
- Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Segmentation of intact cell nuclei in three-dimensional (3D) images of thick tissue sections is an important basic capability necessary for many biological research studies. Because automatic algorithms do not correctly segment all nuclei in tissue sections, interactive algorithms may be preferable for some applications. Existing interactive segmentation algorithms require the analyst to draw a border around the nucleus under consideration in all successive two-dimensional (2D) planes of the 3D image. The present paper describes an algorithm with two main advantages over the existing method. First, the analyst draws borders only in 2D planes that cut approximately through the center of the nucleus under consideration so that the nuclear borders generally are most distinct. Second, the analyst draws only five borders around each nucleus, and then the algorithm interpolates the entire surface. The algorithm results in segmented objects that correspond to individual, visually identifiable nuclei. The segmented surfaces, however, may not exactly represent the true nuclear surface. An optional, automatic surface optimization algorithm can be applied to reduce this error.
Collapse
Affiliation(s)
- S J Lockett
- Life Sciences Division, Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley 94720, California, USA.
| | | | | | | | | |
Collapse
|
47
|
Barsky SH, Sternlicht MD, Safarians S, Nguyen M, Chin K, Stewart SD, Hiti AL, Gray JW. Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype. Oncogene 1997; 15:2077-91. [PMID: 9366525 DOI: 10.1038/sj.onc.1201379] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The highly metastatic amelanotic C8161 human melanoma line was found to exhibit complete dominance of its undifferentiated and metastatic phenotype in multiple somatic cell hybridization studies designed to bypass the presence of potential tumor suppressor genes. In a three armed approach involving somatic cell fusions of C8161 with recipient lines of greater differentiation, different lineage, and different tumorigenicity status, the metastatic and undifferentiated phenotype of C8161 was promiscuously dominant. In somatic cell hybrids produced between the C8161 and a group of non-metastatic human melanoma lines which exhibited melanocyte differentiation markers including S100, HMB-45, NKI/C3, and melanin, the fusions were uniformly metastatic and undifferentiated. In somatic cell hybrids of C8161 and MCF-7 the fusions exhibited an estrogen independent and unresponsive, estrogen receptor (ER) negative, and highly metastatic phenotype. In fusions between C8161 and HMS-1, an immortalized 'benign' human myoepithelial line which produced an abundant extracellular matrix (ECM) and high levels of protease and angiogenic inhibitors including maspin, tissue inhibitor of metalloproteinase-1 (TIMP-1), alpha1-antitrypsin (alpha1-AT), protease nexin II (PN-II), thrombospondin-1 and soluble basic fibroblast growth factor (bFGF) receptors, the hybrids showed complete absence of matrix, absent maspin expression, markedly decreased protease inhibitor and angiogenic inhibitor production, high levels of proteases and angiogenic factors, and a highly metastatic phenotype. In our somatic cell fusions, the human-human hybrids represented true and complete fusions and not hybrid clones selected for by loss of dominant-acting growth suppressor genes. This finding was supported by detailed comparative genomic hybridization (CGH) studies, Q-banding karyotype analysis, and autofusions of representative clones. The purposeful creation of inherently unstable human-murine fusions between C8161 and B16-F1 where loss of putative suppressor loci would be expected, resulted in fusions exhibiting decreased growth and non-metastatic behavior with progressive chromosomal loss. Neither p53, nm23, DNA methyltransferase, activated ras, fibroblast growth factor-4 (FGF-4), or epidermal growth factor receptor (EGFR) mediated the acquisition of the metastatic or undifferentiated phenotype within the C8161-human fusions. These studies are the first studies ever to successfully transfer the complete metastatic phenotype by somatic cell fusion and support the presence of a new high level regulatory pathway(s) involving dominant trans-acting factors which act pleiotropically to regulate an undifferentiated and highly metastatic phenotype.
Collapse
Affiliation(s)
- S H Barsky
- Department of Pathology, University of California Los Angeles School of Medicine 90024, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Yu LC, Moore DH, Magrane G, Cronin J, Pinkel D, Lebo RV, Gray JW. Objective aneuploidy detection for fetal and neonatal screening using comparative genomic hybridization (CGH). Cytometry 1997; 28:191-7. [PMID: 9222103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Comparative genomic hybridization (CGH) allows entire genomes to be scanned for whole and segmental aneuploidy and thus may be an appropriate tool for the detection of clinically important abnormalities during fetal and neonatal screening. Criteria to distinguish between significant aberrations and experimental artifacts are essential for these applications. This report describes the use of a t-statistic to detect changes in CGH profiles that differ significantly from variations that occur in CGH profiles of normal samples. Eleven cell lines derived from fetal or neonatal patients were analyzed in this study. Aneuploidies in these lines included trisomies for chromosomes 13, 16, 18, and 21 and monosomy for distal 5p and tetrasomy 18p. Aneuploidy was detected in all samples by using the t-statistic, although the extent of the aneuploid region was not correctly estimated in some cases. A detailed description of the t-statistic fused for making these CGH comparisons is described in a companion paper (Moore et al., Cytometry 28:183-190, 1997.
Collapse
Affiliation(s)
- L C Yu
- Department of Laboratory Medicine, University of California, San Francisco 84143-0808, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
An objective method for interpreting comparative genomic hybridization (CGH) is described and compared with current methods of interpretation. The method is based on a two-sample t-statistic in which composite test:reference and reference:reference CGH profiles are compared at each point along the genome to detect regions of significant differences. Composite profiles are created by combining CGH profiles measured from several metaphase chromosomes for each type of chromosome in the normal human karyotype. Composites for both test:reference and reference:reference CGH analyses are used to generate mean CGH profiles and information about the variance therein. The utility of the method is demonstrated through analysis of aneusomies and partial gain and loss of DNA sequence in a myeloid leukemia specimen. Banding analyses of this specimen indicated inv (3)(q21q26), del (5)(q2?q35), -7, +8 and add (17)(p11.2). The t-statistic analyses of CGH data indicated rev ish enh (8) and rev ish dim (5q31.1q33.1,7q11.23qter). The undetected gain on 17p was small and confined to a single band (17p11.2). Thus, the t-statistic is an objective and effective method for defining significant differences between test and reference CGH profiles.
Collapse
Affiliation(s)
- D H Moore
- Department of Epidemiology, University of California, San Francisco 94143-0808, USA
| | | | | | | |
Collapse
|
50
|
Shi YP, Naik P, Dietrich WF, Gray JW, Hanahan D, Pinkel D. DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice. Genes Chromosomes Cancer 1997; 19:104-11. [PMID: 9172001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Comparative genomic hybridization (CGH) provides a method of surveying the entire tumor genome for regional variations in DNA sequence copy number. Such variations, if found recurrently, may indicate the locations of genes that contribute to tumor development through upregulation of oncogenes (copy number increase), inactivation of tumor-suppressor genes (copy number decrease), or changes in the level of expression through gene dosage effects. Thus, CGH is a powerful tool for screening for new cancer genes. Although CGH is widely applied to human genome analysis, application to the mouse is only beginning. The present study is designed to compare results obtained by CGH with those obtained by other techniques used for analysis of the murine genome. We report CGH analysis of several control cell lines with cytogenetically established regional copy number changes, as well as analysis of 16 primary insulinomas, four tumor-derived cell lines, and three hyperplasia-derived cell lines from transgenic mice expressing the SV40 large T antigen under control of the rat insulin promoter. Loss of heterozygosity (LOH) on chromosomes 9 and 16 had previously been found to be frequent in primary insulinomas, and specimens were selected for the present study based on the LOH status of these chromosomes. We found complete concordance of the CGH results with the cytogenetically described copy number changes in the control cell lines and with the LOH on chromosomes 9 and 16 in the tumors. Thus, CGH can provide accurate data in murine systems, and it reveals that the LOH in these islet cell tumors most frequently results from deletion of one of the alleles.
Collapse
Affiliation(s)
- Y P Shi
- Department of Laboratory Medicine, University of California at San Francisco 94143, USA
| | | | | | | | | | | |
Collapse
|